Opdivo-Yervoy (nivolumab-ipilimumab)

pCPA File Number: 21557
Negotiation Status:
Under consideration for negotiation
Indication(s):
OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with unresectable malignant pleural mesothelioma (MPM) who have not received prior systemic therapy for MPM
Sponsor/Manufacturer:
Bristol Myers Squibb Canada Inc.
CADTH Project Number:
PC0229-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable